Citations

Clear

9 citation(s) found for "Sun, Feng".

Reduced Expression of CLEC4G in Neurons Is Associated with Alzheimer’s Disease
Feng, Xinwei , Huang, Yuying , Zhang, Ge , Deng, Wenbin , Deng, Wenbin , Qi, Fangfang

Mayo Clinic

International Journal of Molecular Sciences | April 24, 2024 | Volume: 25 | Issue: 9 | Pages: 4621

10.3390/ijms25094621 | PMID 38731839 Get It

CLEC4G, a glycan-binding receptor, has previously been demonstrated to inhibit Aβ generation, yet its brain localization and functions in Alzheimer’s disease (AD) are not clear. We explored the localization, function, and regulatory network of CLEC4G via experiments and analysis of RNA-seq databases. CLEC4G transcripts and proteins were identified in brain tissues, with the highest expression observed in neurons. Notably, AD was associated with reduced levels of CLEC4G transcripts. Bioinformatic analyses revealed interactions between CLEC4G and relevant genes such as BACE1, NPC1, PILRA, TYROBP, MGAT1, and MGAT3, all displaying a negative correlation trend. We further identified the upstream transcriptional regulators NR2F6 and XRCC4 for CLEC4G and confirmed a decrease in CLEC4G expression in APP/PS1 transgenic mice. This study highlights the role of CLEC4G in protecting against AD progression and the significance of CLEC4G for AD research and management.
Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
Park, Jung Eun , Nguyen, Vy H. , Tsai, Pei‐Chien , Toyoda, Hidenori , Leong, Jennifer , Guy, Jennifer , Huang, Chung‐Feng , Yasuda, Satoshi , Abe, Hiroshi , Hsu, Yao‐Chun , Tseng, Cheng‐Hao , Liu, Joanne, Chen, Yao‐Li , Lin, Ping‐Yi , Yoshimaru, Yoko , Ishigami, Masatoshi , Enomoto, Masaru , Tamori, Akihiro , Uojima, Haruki , Wang, Xiao Zhong, Xu, Qiang , Takahashi, Hirokazu , Eguchi, Yuichiro , Inoue, Kaori , Zhao, Wen , Barnett, Scott D. , Maeda, Mayumi , Cheung, Ramsey , Landis, Charles , Tanaka, Yasuhito , Roberts, Lewis R. , Schwartz, Myron , Yu, Ming‐Lung , Nguyen, Mindie H. , Yeh, Ming-Lun , Huang, C-F , Tseng, Cheng-Hao , Jun, D W , Ogawa, Eiichi , Huang, Daniel Q , Dai, Chia-Yen , Kumada, Takashi , Yu, M-L , Nguyen, Mindie H , Roberts, Lewis R , Huang, Daniel Q. , Chuang, Wan‐Long , Huang, Jee‐Fu

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 4, 2024 | Volume: 59 | Issue: 6 | Pages: 742-751

10.1111/apt.17863 | PMID 38173278 Get It

SummaryBackgroundRacial and ethnic disparities exist for hepatitis C virus (HCV) treatment and hepatocellular carcinoma (HCC) survival.AimTo evaluate the impact of HCV treatment on such disparities.MethodsIn a retrospective cohort study, we analysed 6069 patients with HCV‐related HCC (54.2% Asian, 30.1% White, 8.5% Black, and 7.3% Hispanic) from centres in the United States and Asia.ResultsThe mean age was 61, 60, 59 and 68, respectively, for White, Black, Hispanic and Asian patients. Black patients were most likely to have Barcelona Clinic Liver Cancer stage D, vascular invasion and distant metastasis (23% vs. 5%–15%, 20% vs. 10%–17% and 10% vs. 5%–7%, respectively; all p < 0.0001). Treatment rate with direct‐acting antiviral agents (DAA) was 35.9% for Asian, 34.9% for White, 30.3% for Hispanic (30.3%), and 18.7% for Black patients (p < 0.0001). Among those untreated or without sustained virologic response (SVR), 10‐year survival rates were 35.4, 27.5, 19.3 and 14.0, respectively, for Asian, Hispanic, White and Black patients (p < 0.0001). There were no statistically significant differences among those with SVR (p = 0.44). On multivariable analysis adjusted for relevant confounders, there was no statistically significant association between survival and being Hispanic (aHR: 0.68, p = 0.26) or Black (aHR: 1.18, p = 0.60) versus White. There was a significant association between being Asian American and survival (aHR: 0.24, p = 0.001; non‐U.S. Asian: aHR: 0.66, p = 0.05), and for SVR (aHR: 0.30, p < 0.0001).ConclusionDAA treatment rates were suboptimal. Racial and ethnic disparities resolved with HCV cure. Early diagnosis and improved access to HCV treatment is needed for all patients with HCV infection.
Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features
Wu, Jiang , Cai, Muyan , Li, Shiyong , Bei, Jin‐Xin , Wang, Fang , Ling, Yihong , Rodrı́guez-Bigas, Miguel A. , Dignam, James J. , Mao, Mao , Li, Jibin , Guo, Yun‐Miao , Wu, Xiaoyan , Kong, Lingheng , Tang, Jing‐Hua, Li, Chao‐Feng, Chen, Jie‐Rong, Ye, Ming‐Zhi, Guo, Fengming, Han, Peng , Wan, Desen, Li, Li , Xu, Rui‐Hua , Ding, Pei-Rong , Group, Written on behalf of AME Colorectal Cancer Cooperative, Xu, Rui‐Hua , Jiang, Wu , Xu, Rui-Hua , Hampel, Heather , Frayling, Ian M. , Sinicrope, Frank A. , Kerr, David , Rosell, Rafael , Kong, Ling‐Heng, Tang, Jing-Hua , Wu, Xiaodan , Ou, Qingjian , Ye, Ming-Zhi, Wang, Qiwei , Pan, Zhizhong , Group, Written on behalf of AME Colorectal Cancer Cooperative

Mayo Clinic

International Journal of Cancer | December 6, 2018 | Volume: 144 | Issue: 9 | Pages: 2161-2168

10.1002/ijc.32044 | PMID 30521064 Get It

The prevalence of Lynch syndrome (LS) varies significantly in different populations, suggesting that ethnic features might play an important role. We enrolled 3330 consecutive Chinese patients who had surgical resection for newly diagnosed colorectal cancer. Universal screening for LS was implemented, including immunohistochemistry for mismatch repair (MMR) proteins, BRAFV600E mutation test and germline sequencing. Among the 3250 eligible patients, MMR protein deficiency (dMMR) was detected in 330 (10.2%) patients. Ninety‐three patients (2.9%) were diagnosed with LS. Nine (9.7%) patients with LS fulfilled Amsterdam criteria II and 76 (81.7%) met the revised Bethesda guidelines. Only 15 (9.7%) patients with absence of MLH1 on IHC had BRAFV600E mutation. One third (33/99) of the MMR gene mutations have not been reported previously. The age of onset indicates risk of LS in patients with dMMR tumors. For patients older than 65 years, only 2 patients (5.7%) fulfilling revised Bethesda guidelines were diagnosed with LS. Selective sequencing of all cases with dMMR diagnosed at or below age 65 years and only of those dMMR cases older than 65 years who fulfill revised Bethesda guidelines results in 8.2% fewer cases requiring germline testing without missing any LS diagnoses. While the prevalence of LS in Chinese patients is similar to that of Western populations, the spectrum of constitutional mutations and frequency of BRAFV600E mutation is different. Patients older than 65 years who do not meet the revised Bethesda guidelines have a low risk of LS, suggesting germline sequencing might not be necessary in this population.
Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience
Chen, Vincent , Yeh, Ming-Lun, Le, An K. , Jun, Mi Jung, Saeed, Waqar Khalid , Yang, Ju Dong , Huang, Chung‐Feng , Lee, H. Y., Tsai, Pei‐Chien , Giama, Nasra H., Kim, N. G., Nguyen, Phuong , Dang, Hansen , Ali, Hamdi A. , Zhang, N., Chuang, Wan‐Long , Roberts, Lewis R. , Yu, Ming‐Lung , Nguyen, Mindie H. , Chen, V L , Huang, C-F , Jun, D W , Yu, M-L , Nguyen, Mindie H , Roberts, Lewis R , Yeh, Ming-Lun , Yang, Ju Dong , Lee, M.‐H., Huang, Jee‐Fu , Dai, Chia-Yen , Lim, Young‐Suk

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 24, 2018 | Volume: 48 | Issue: 1 | Pages: 44-54

10.1111/apt.14801 | PMID 29797518 Get It

SummaryBackgroundHepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide. It remains incompletely understood in the real world how anti‐viral therapy affects survival after HCC diagnosis.MethodsThis was an international multicentre cohort study of 2518 HBV‐related HCC cases diagnosed between 2000 and 2015. Cox proportional hazards models were utilised to estimate hazard ratios (HR) with 95% (CI) for anti‐viral therapy and cirrhosis on patients' risk of death.ResultsApproximately, 48% of patients received anti‐viral therapy at any time, but only 17% were on therapy at HCC diagnosis (38% at US centres, 11% at Asian centres). Anti‐viral therapy would have been indicated for >60% of the patients not on anti‐viral therapy based on American criteria. Patients with cirrhosis had lower 5‐year survival (34% vs 46%; P < 0.001) while patients receiving anti‐viral therapy had increased 5‐year survival compared to untreated patients (42% vs 25% with cirrhosis and 58% vs 36% without cirrhosis; P < 0.001 for both). Similar findings were seen for other patient subgroups by cancer stages and cancer treatment types. Anti‐viral therapy was associated with a decrease in risk of death, whether started before or after HCC diagnosis (adjusted HR 0.62 and 0.79, respectively; P < 0.001).ConclusionsAnti‐viral therapy improved overall survival in patients with HBV‐related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti‐viral therapy in HBV‐related HCC and better linkage‐to‐care for HBV patients are needed.
Historical epidemiology of hepatitis C virus in select countries—volume 4
Vince, Adriana , Himatt, Sayed , Mohamed, Rosmawati , Opare‐Sem, Ohene , Workneh, A., Njouom, Richard , Ghazzawi, Imad, Abdulla, Maheeba , Kaliaskarova, Kulpash , Owusu‐Ofori, Shirley , Abdelmageed, Marwa , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Kaabi, S. Al, Naamani, Khalid Al , Qamish, Jehad Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Busafi, Said A. , Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Bane, Abate, Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Cardenas, I., Chan, Henry Lik‐Yuen , Chen, C. J., Chen, Ding‐Shinn , Chen, Pei‐Jer , Cuellar, Diego , Derbala, M., Elbardiny, A. A., Estes, Chris , Farag, E., Gamkrelidze, Ivane , Garcìa, V. , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Hamoudi, Waseem , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee Tak , Jahis, Rohani, Jelev, Deian, John, Anil K , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Layden, Jennifer E. , Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching‐kong, Lukšić, Boris, Malu, Abraham O., Mateva, Lyudmila, Mitova, R, Morović, Miro, Murphy, K., Mustapha, B., Nde, H. , Nersesov, Alexander , Ngige, Evelyn, Njoya, Oudou, Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omede, O. , Omuemu, C., Phillips, Richard Odame , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Redae, Berhane, Reić, Tatjana, Wit, Tobias Rinke de, Ríos, Cielo , Robbins, S., Roberts, Lewis R. , Sanad, S. J., Schmelzer, Jonathan, Sharma, Manik , Simonova, Marieta, Su, Tung‐Hung , Sultan, K., Tan, S. S. , Tchernev, К., Tsang, O. T. Y., Tsang, S., Tzeuton, Christian, Ugoeze, S., Vi, R., Wani, Hamid, Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Razavi‐Shearer, Kathryn , Wong, Grace Lai‐Hung , Roberts, Lewis R , Fung, James , Akın, Onur , Blach, Sarah , Chien, Rong‐Nan , Chuang, Wan‐Long , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 8-24

10.1111/jvh.12762 | PMID 29105285 Get It

SummaryDue to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country‐specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Hong Kong to 2.4% in Taiwan, while the largest viraemic populations were in Nigeria (2 597 000 cases) and Taiwan (569 000 cases). Diagnosis, treatment and liver transplant rates varied widely across the countries included in this analysis, as did the availability of reliable data. Addressing data gaps will be critical for the development of future strategies to manage and minimize the disease burden of hepatitis C.
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4
Chan, Henry Lik‐Yuen , Chen, C. J., Omede, O. , Qamish, Jehad Al, Naamani, Khalid Al , Bane, Abate, Tan, S. S. , Simonova, Marieta, Cardenas, I., Derbala, Moutaz , Phillips, Richard Odame , Abdelmageed, Marwa , Abdulla, Maheeba , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Ghazzawi, Imad, Kaabi, S. Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Busafi, Said A. , Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Blach, Sarah , Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Chen, Ding‐Shinn , Chen, Pei‐Jer , Cuellar, Diego , Elbardiny, A. A., Farag, Elmoubasher , Gamkrelidze, Ivane , Garcìa, V. , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Hamoudi, Waseem , Himatt, Sayed , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee Tak , Jahis, Rohani, Jelev, Deian, John, Anil K , Kaliaskarova, Kulpash , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Layden, Jennifer E. , Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching Kong, Lukšić, Boris, Maaroufi, Abderrahmane , Malu, Abraham O., Mateva, Lyudmila, Mitova, R, Mohamed, Rosmawati , Morović, Miro, Murphy, K., Mustapha, B., Nersesov, Alexander , Ngige, Evelyn, Njouom, Richard , Njoya, Oudou, Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omuemu, C., Opare‐Sem, Ohene , Owusu‐Ofori, Shirley , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Razavi‐Shearer, Kathryn , Redae, Berhane, Reić, Tatjana, Wit, Tobias Rinke de, Ríos, Cielo , Robbins, S., Roberts, Lewis R. , Sanad, S. J., Schmelzer, Jonathan, Sharma, Manik , Su, Tung‐Hung , Sultan, K., Tchernev, К., Tsang, O. T. Y., Tsang, Simon H. Y., Tzeuton, Christian, Ugoeze, S., Vi, R., Vince, Adriana , Wani, Hamid, Workneh, A., Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Nde, H. , Wong, Grace Lai‐Hung , Blach, S , Roberts, Lewis R , Akın, Onur , Chien, Rong‐Nan , Chuang, Wan‐Long , Estes, Chris , Fung, James , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 25-43

10.1111/jvh.12760 | PMID 29105283 Get It

SummaryFactors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030. Model inputs were agreed upon through expert consensus, and a standardized methodology was followed to allow for comparison across countries. The viremic prevalence is expected to remain constant or decline in all but four countries (Ethiopia, Ghana, Jordan and Oman); however, HCV‐related morbidity and mortality will increase in all countries except Qatar and Taiwan. In Qatar, the high‐treatment rate will contribute to a reduction in total cases and HCV‐related morbidity by 2030. In the remaining countries, however, the current treatment paradigm will be insufficient to achieve large reductions in HCV‐related morbidity and mortality.
Strategies to manage hepatitis C virus infection disease burden—Volume 4
Chen, Ding‐Shinn , Hamoudi, Waseem , Mustapha, B., Layden, Jennifer E. , Nersesov, Alexander , Reić, Tatjana, Garcìa, V. , Ríos, Cielo , Mateva, Lyudmila, Njoya, Oudou, Al‐Busafi, Said A. , Abdelmageed, Marwa , Abdulla, Maheeba , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Ghazzawi, Imad, Kaabi, S. Al, Naamani, Khalid Al , Qamish, Jehad Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Bane, Abate, Blach, Sarah , Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Cardenas, I., Chan, Henry Lik‐Yuen , Chen, C. J., Chen, Pei‐Jer , Cuellar, Diego , Derbala, M., Elbardiny, A. A., Farag, E., Gamkrelidze, Ivane , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Himatt, Sayed , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee‐Tak, Jahis, Rohani, Jelev, Deian, John, Anil K , Kaliaskarova, Kulpash , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching‐kong, Lukšić, Boris, Maaroufi, Abderrahmane , Malu, Abraham O., Mitova, R, Mohamed, Rosmawati , Morović, Miro, Murphy, K., Nde, H. , Ngige, Evelyn, Njouom, Richard , Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omede, O. , Omuemu, C., Opare‐Sem, Ohene , Owusu‐Ofori, Shirley , Phillips, Richard Odame , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Razavi‐Shearer, Kathryn , Redae, Berhane, Wit, Tobias Rinke de, Robbins, S., Roberts, Lewis R. , Sanad, S. J., Sharma, Manik , Simonova, Marieta, Su, Tung‐Hung , Sultan, K., Tan, S. S. , Tchernev, К., Tsang, O. T. Y., Tsang, Simon H. Y., Tzeuton, Christian, Ugoeze, S., Vi, R., Vince, Adriana , Wani, Hamid, Workneh, A., Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Schmelzer, Jonathan, Hui, Yee Tak , Wong, Grace Lai‐Hung , Blach, S , Roberts, Lewis R , Akın, Onur , Chien, Rong‐Nan , Chuang, Wan‐Long , Estes, Chris , Fung, James , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 44-63

10.1111/jvh.12759 | PMID 29105286 Get It

SummaryThe hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets—“WHO Targets” (65% reduction in HCV‐related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies. The scenarios developed to achieve the WHO Targets in all countries studied assumed the implementation of national policies to prevent new infections and to diagnose current infections through screening.
More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma
Jun, Tomi , Yang, Ju Dong , Chen, Vincent , Nguyen, Pauline, Giama, Nasra H., Huang, Chung‐Feng , Hsing, Ann W. , Chuang, Wan‐Long , Roberts, Lewis R. , Yu, Ming‐Lung , Nguyen, Mindie H. , Nguyen, Mindie H , Roberts, Lewis R , Chen, V L , Yu, M-L , Yeh, Ming-Lun , Yang, Ju Dong , Dai, Chia-Yen , Huang, Jee‐Fu

Mayo Clinic

Liver International | October 16, 2017 | Volume: 38 | Issue: 5 | Pages: 895-902

10.1111/liv.13613 | PMID 29045023 Get It

AbstractBackground & AimsAlthough hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major risk factors for hepatocellular carcinoma (HCC), non‐viral causes of HCC, particularly non‐alcoholic fatty liver disease (NAFLD), are becoming increasingly prevalent. The aim of this study was to compare the clinical characteristics and survival of cryptogenic and viral HCC.MethodsWe conducted a retrospective cohort study involving 3878 consecutive HCC patients seen at two tertiary centres in the United States and one in Taiwan from 2004 to 2014. We compared the clinical characteristics, treatment and survival of patients by underlying aetiology: cryptogenic (n = 696), HBV (n = 1304) or HCV (n = 1878).ResultsCirrhosis was present in 66.8% of the cryptogenic HCC patients, compared with 74.7% of HBV‐related HCC (HBV‐HCC) (P = .001) and 85.9% of HCV‐HCC (P < .001). Compared to viral HCC, cryptogenic HCC patients presented with larger tumours and at later stages of disease. Five‐year overall survival was 16.3% among cryptogenic HCC patients compared with 31.9% among HBV‐HCC patients and 27.7% among HCV‐HCC patients (P < .001 for both by the log‐rank test). HCC aetiology was not an independent predictor of survival, though ethnicity, cirrhosis status, meeting Milan criteria and treatment allocation were.ConclusionsCompared with viral HCC patients, those with cryptogenic HCC had lower prevalence of cirrhosis, were diagnosed with larger tumours at more advanced stages of disease, and had poorer overall survival. Additional efforts are needed to identify patients at risk of cryptogenic HCC and to identify cryptogenic HCC at earlier stages of disease.
Paracrine interactions among parathyroid cells: Effect of cell density on cell secretion
Sun, Feng , Maercklein, Peter B., Fitzpatrick, Lorraine A.

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 9 | Issue: 7 | Pages: 971-976

10.1002/jbmr.5650090703 | PMID 7942165 Get It

Abstract Cell-cell interactions are important in the regulation of endocrine cell secretion. To investigate the possibility that cell communication may alter the regulation of parathyroid cell secretion, we utilized the reverse hemolytic plaque assay (RHPA) to measure parathyroid hormone (PTH) release from individual cells. Bovine parathyroid cells were dispersed and plated with protein A-conjugated erythrocytes at cell densities ranging from 0.9 to 36 X 102 cells/cm2 in 0.2 mM calcium. Cell populations were greater than 98% homogeneous as determined by immunocytochemistry and in situ hybridization for PTH mRNA. Plaques were developed and data analyzed for the amount of PTH per cell released (plaque area in μm2 X 104) and the determination of cell recruitment (% plaques formed). A positive correlation existed between parathyroid cell density and the amount of PTH released. As the distance between cells increased, the plaque area (amount of PTH released per cell) decreased (ranging from 1.0 X 1044 μm2 at 0.9 X 102 cells/cm2 versus 1.6 X 104 μm2 at 36 X 102 cells/cm2). The percentage of cells releasing PTH (recruitment) also decreased (16% at 0.9 X 102 cells/cm2 versus 47% at 36 X 102 cells/cm2). These data suggest that parathyroid cells in close proximity are stimulated to secrete more hormone than those at lesser densities. In addition, parathyroid cells are recruited to secrete PTH when plated at high density. Factor(s) released by the parathyroid cell may increase cell responsiveness and stimulate secretion in a paracrine fashion.